JP2006524565A - アンチ溶媒凝固プロセス - Google Patents
アンチ溶媒凝固プロセス Download PDFInfo
- Publication number
- JP2006524565A JP2006524565A JP2006505309A JP2006505309A JP2006524565A JP 2006524565 A JP2006524565 A JP 2006524565A JP 2006505309 A JP2006505309 A JP 2006505309A JP 2006505309 A JP2006505309 A JP 2006505309A JP 2006524565 A JP2006524565 A JP 2006524565A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- solvent
- liquid medium
- process according
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IQWHHAHJEKUSQP-MBRGTKAKSA-N CCC(CCC(CCC1)C([C@H](C)C2)C1C(CC1)=C2CC1=O)(C#C)O Chemical compound CCC(CCC(CCC1)C([C@H](C)C2)C1C(CC1)=C2CC1=O)(C#C)O IQWHHAHJEKUSQP-MBRGTKAKSA-N 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/0063—Control or regulation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
- B01D9/0054—Use of anti-solvent
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
- C01D3/00—Halides of sodium, potassium or alkali metals in general
- C01D3/22—Preparation in the form of granules, pieces, or other shaped products
- C01D3/24—Influencing the crystallisation process
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Steroid Compounds (AREA)
- Glanulating (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Colloid Chemistry (AREA)
Abstract
Description
a)少なくとも1の溶解された有機または無機化合物を含む第1の液状媒体が膜を通して1以上のアンチ溶媒中に押出されて、または1以上のアンチ溶媒が膜を通して少なくとも1の有機または無機化合物を含む液状媒体中に押出されて、当該有機および/または無機化合物を含む固形粒子を含む組成物が生成する。
b)その後、さらなる段階で、調製された固形粒子の少なくとも一部が、その中にコーティング材料が溶解している第2の液状媒体を膜を通して、当該コーティング材料に対するアンチ溶媒中の当該固形粒子の懸濁液中に押出すことによって、コーティング材料の1以上の固形コーティングでコーティングされて、コーティングされた固形粒子を含む組成物が生成する。
Claims (19)
- 少なくとも1の有機若しくは無機化合物を含む固形組成物を調製するためのアンチ溶媒凝固プロセスにおいて、少なくとも1の溶解された有機若しくは無機化合物を含む液状媒体が膜を通して1以上のアンチ溶媒中に押出されて、または1以上のアンチ溶媒が膜を通して少なくとも1の有機若しくは無機化合物を含む液状媒体中に押出されて、当該有機および/または無機化合物を含む固形粒子を含む組成物を生成する方法。
- 凝固が結晶化であり、調製された固形粒子が結晶粒子であり、有機または無機化合物が結晶化可能な化合物であり、および任意的に、当該結晶粒子が本プロセスから回収されてもよい、請求項1に従うプロセス。
- プロセスが連続プロセスとして実施される、請求項1〜2のいずれか1項に従うプロセス。
- 液状媒体が1以上のアンチ溶媒からナノろ過によって分離され、および任意的に、液状媒体および/またはアンチ溶媒が再循環されてもよい、請求項1〜3のいずれか1項に従うプロセス。
- 当該粒子を含む当該組成物が得られる前に、エマルションが形成される、請求項1〜4のいずれか1項に従うプロセス。
- 非溶媒が、液状媒体中におよび/または1以上のアンチ溶媒中に存在する、請求項1〜5のいずれか1項に従うプロセス。
- 有機または無機化合物が、遷移金属化合物、遷移金属塩、アルカリ金属塩、アルカリ土類金属塩、脂肪酸、たんぱく質、糖類、アミノ酸、および顔料からなる群から選ばれる、請求項1〜6のいずれか1項に従うプロセス。
- 固形粒子が、ただ1つの無機または有機化合物の粒子から本質的になる、請求項1〜7のいずれか1項に従うプロセス。
- 無機または有機化合物が医薬化合物である、請求項1〜8のいずれか1項に従うプロセス。
- 医薬化合物が、チボロン、プロゲステロン、デソゲストレル、および3−ケト−デソゲストレル(エトノゲストレル)からなる群から選ばれる、請求項9に従うプロセス。
- 固形組成物が、2以上の医薬化合物の混合物を含む、請求項1〜8のいずれか1項に従うプロセス。
- 固形粒子を含む組成物が調製され、当該組成物の中で粒子の少なくとも一部が、溶解された有機または無機コーティング材料を含む液状媒体を膜を通して、当該コーティング材料に対する1以上のアンチ溶媒中のコーティングされるべき粒子の懸濁液中に押出すことによって、1以上の有機または無機コーティング材料の1以上の固形コーティングでコーティングされた核からなる、請求項1〜4のいずれか1項に従うプロセス。
- 調製された固形組成物が、医薬化合物を含む少なくとも1のコーティング材料でコーティングされた医薬化合物を含む核を持つ粒子を含む、請求項12に従うプロセス。
- 請求項1〜13のいずれか1項に従うプロセスによって得ることができる組成物。
- 結晶化段階直後の粒子サイズ分布の幅が、好ましくは3未満、より好ましくは2未満である、請求項2に従うプロセスによって得ることができる結晶粒子。
- チボロン、プロゲステロン、デソゲストレル、および3−ケト−デソゲストレル(エトノゲストレル)からなる群から好ましくは選ばれる少なくとも1の医薬化合物を含む、請求項15に従う結晶粒子。
- 請求項14〜16のいずれか1項に従う結晶粒子を含む投与形態の薬物。
- 投与形態が錠剤である、請求項17に従う投与形態の薬物。
- 請求項1〜13のいずれか1項に従うプロセスまたは請求項14〜16のいずれか1項に従う結晶粒子を、投与形態の薬物の調製に使用する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46676103P | 2003-04-29 | 2003-04-29 | |
US60/466,761 | 2003-04-29 | ||
PCT/EP2004/004506 WO2004096405A1 (en) | 2003-04-29 | 2004-04-28 | Antisolvent solidification process |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2006524565A true JP2006524565A (ja) | 2006-11-02 |
JP2006524565A5 JP2006524565A5 (ja) | 2007-07-05 |
JP5207432B2 JP5207432B2 (ja) | 2013-06-12 |
Family
ID=33418418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006505309A Expired - Fee Related JP5207432B2 (ja) | 2003-04-29 | 2004-04-28 | アンチ溶媒凝固プロセス |
Country Status (23)
Country | Link |
---|---|
US (4) | US20060182808A1 (ja) |
EP (1) | EP1620193B1 (ja) |
JP (1) | JP5207432B2 (ja) |
KR (1) | KR20060006949A (ja) |
CN (1) | CN100434133C (ja) |
AR (1) | AR044140A1 (ja) |
AT (1) | ATE406946T1 (ja) |
AU (1) | AU2004234057A1 (ja) |
BR (1) | BRPI0409860A (ja) |
CA (1) | CA2523883C (ja) |
CL (1) | CL2004000912A1 (ja) |
DE (1) | DE602004016311D1 (ja) |
ES (1) | ES2312996T3 (ja) |
HK (1) | HK1088268A1 (ja) |
IL (1) | IL171613A (ja) |
MX (1) | MXPA05011626A (ja) |
MY (1) | MY141189A (ja) |
NO (1) | NO20055607L (ja) |
NZ (1) | NZ543772A (ja) |
RU (1) | RU2339364C2 (ja) |
TW (1) | TW200500095A (ja) |
WO (1) | WO2004096405A1 (ja) |
ZA (1) | ZA200509597B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7942990B2 (en) | 2006-12-18 | 2011-05-17 | Daicel Chemical Industries, Ltd. | Hybrid inflator |
WO2019239550A1 (ja) * | 2018-06-14 | 2019-12-19 | 日揮株式会社 | 晶析装置及び晶析方法 |
JP2021500924A (ja) * | 2017-10-27 | 2021-01-14 | フリト−レー・ノース・アメリカ・インコーポレイテッドFrito−Lay North America, Inc. | ナトリウム低減用の結晶形態 |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103462943A (zh) * | 2005-07-15 | 2013-12-25 | Map药物公司 | 在离散的吸入粒子中结合的多种活性药物成分及其制剂 |
EP1904219A4 (en) * | 2005-07-15 | 2011-07-27 | Map Pharmaceuticals Inc | METHOD FOR FORMING PARTICLES |
ES2381892T3 (es) * | 2007-01-22 | 2012-06-01 | Cargill, Incorporated | Procedimiento para producir composiciones de rebaudiósido A purificado que utiliza la cristalización disolvente/antidisolvente |
GB0705159D0 (en) * | 2007-03-19 | 2007-04-25 | Prosonix Ltd | Process for making crystals |
FI120527B (fi) * | 2007-06-18 | 2009-11-30 | Crisolteq Oy | Talteenottomenetelmä |
GB0711680D0 (en) * | 2007-06-18 | 2007-07-25 | Prosonix Ltd | Process |
US20100291221A1 (en) * | 2009-05-15 | 2010-11-18 | Robert Owen Cook | Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation |
TWI466709B (zh) * | 2011-07-20 | 2015-01-01 | Nat Univ Chung Hsing | From the original berry Wolfberry a liquid - liquid freezing method for separation of high purity theaflavins palmitate Maize |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
MX365818B (es) | 2011-11-23 | 2019-05-30 | Therapeuticsmd Inc | Formulaciones y terapias de reemplazo hormonal de combinacion naturales. |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9452930B2 (en) * | 2013-11-04 | 2016-09-27 | New Jersey Institute Of Technology | System and method for continuous polymer coating of particles |
US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
PT108368B (pt) | 2015-03-31 | 2018-11-05 | Hovione Farm S A | Produção contínua de partículas |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
CN106853295A (zh) * | 2015-12-09 | 2017-06-16 | 北大方正集团有限公司 | 一种基于膜分散的结晶方法 |
AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
WO2020135352A1 (zh) * | 2018-12-28 | 2020-07-02 | 四川科伦药物研究院有限公司 | 制备黄体酮颗粒物的方法、所得黄体酮颗粒物及其注射剂 |
CN111234431A (zh) * | 2020-03-31 | 2020-06-05 | 宁夏颐星新材料科技有限公司 | 一种消泡型聚乙烯醇粉末的生产工艺 |
GB202004824D0 (en) * | 2020-04-01 | 2020-05-13 | Naturbeads Ltd | Biopolymer particle preparation |
GB202011836D0 (en) | 2020-07-30 | 2020-09-16 | Micropore Tech Limited | Crystallisation methods |
CN115777906A (zh) * | 2021-09-10 | 2023-03-14 | 吉林大学 | 氯化钠纳微米粒子及其制备方法和应用 |
CN117942426B (zh) * | 2024-03-22 | 2024-05-31 | 四川大学 | 一种具有取向孔道结构的多级多孔材料及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04154605A (ja) * | 1990-10-16 | 1992-05-27 | Agency Of Ind Science & Technol | 無機質微小球体の製造方法 |
JPH04193336A (ja) * | 1990-11-28 | 1992-07-13 | Fuji Photo Film Co Ltd | 溶液の均一混合装置および弾性体多孔膜 |
JPH07504162A (ja) * | 1991-12-18 | 1995-05-11 | ワーナー―ランバート・コンパニー | 新規な薬学的固体分散物 |
JPH11503448A (ja) * | 1995-04-13 | 1999-03-26 | アストラ・アクチエボラーグ | 吸引可能粒子の製造法 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2716453B1 (fr) * | 1994-02-22 | 1996-03-29 | Rhone Poulenc Agrochimie | Procédé de sulfinylation de composés hétérocycliques. |
US4089843A (en) * | 1976-09-20 | 1978-05-16 | The Upjohn Company | Precipitating polymers in powder form |
US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
US4783484A (en) * | 1984-10-05 | 1988-11-08 | University Of Rochester | Particulate composition and use thereof as antimicrobial agent |
JPH0672528B2 (ja) * | 1985-07-16 | 1994-09-14 | 三信工業株式会社 | 船舶のエンジン |
US5269926A (en) * | 1991-09-09 | 1993-12-14 | Wisconsin Alumni Research Foundation | Supported microporous ceramic membranes |
FR2658498B1 (fr) * | 1990-02-19 | 1992-05-15 | Atochem | Particules de chlorure de magnesium a structure tronc conique, composante catalytique supportee sur ces particules, polyolefines obtenues a partir de cette composante catalytique, procedes de fabrication de ces produits. |
IE71202B1 (en) * | 1990-12-17 | 1997-02-12 | Akzo Nv | Progestagen-only contraceptive |
WO1993000156A1 (en) * | 1991-06-29 | 1993-01-07 | Miyazaki-Ken | Monodisperse single and double emulsions and production thereof |
DK95093D0 (da) * | 1993-08-20 | 1993-08-20 | Novo Nordisk As | Farmaceutisk formulering indeholdende et hormon |
JPH09508055A (ja) * | 1993-11-08 | 1997-08-19 | ザ、ジレット、カンパニー | 超臨界流体を用いる粒子の形成法、これによって形成されるエーロゲル粒子、およびエーロゲル粒子を含む制汗剤 |
JP3492787B2 (ja) * | 1994-04-15 | 2004-02-03 | 信越化学工業株式会社 | 固形製剤のコーティング用水性エマルジョンの濃縮方法 |
US6387399B1 (en) * | 1994-12-02 | 2002-05-14 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Microencapsulated bioactive agents and method of making |
US5876480A (en) * | 1996-02-20 | 1999-03-02 | The United States Of America As Represented By The Secretary Of The Navy | Synthesis of unagglomerated metal nano-particles at membrane interfaces |
GB9610955D0 (en) * | 1996-05-24 | 1996-07-31 | Hercules Inc | Sizing composition |
IL123984A (en) * | 1997-04-22 | 2004-09-27 | Akzo Nobel Nv | Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable |
US5879715A (en) * | 1997-09-02 | 1999-03-09 | Ceramem Corporation | Process and system for production of inorganic nanoparticles |
CA2326349A1 (en) * | 1998-04-09 | 1999-10-21 | F. Hoffmann-La Roche Ag | Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants |
SE9801287D0 (sv) * | 1998-04-14 | 1998-04-14 | Astra Ab | Incorporation of active substances in carrier matrixes |
US6113795A (en) * | 1998-11-17 | 2000-09-05 | The University Of Kansas | Process and apparatus for size selective separation of micro- and nano-particles |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
IN191236B (ja) * | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
US6780507B2 (en) * | 2000-02-09 | 2004-08-24 | Analytical Research Systems, Inc. | Hydrocapsules and method of preparation thereof |
US6623761B2 (en) * | 2000-12-22 | 2003-09-23 | Hassan Emadeldin M. | Method of making nanoparticles of substantially water insoluble materials |
GB0102075D0 (en) * | 2001-01-26 | 2001-03-14 | Astrazeneca Ab | Process |
US20030049323A1 (en) * | 2001-08-29 | 2003-03-13 | Hitt James E. | Process to precipitate drug particles |
KR20050035146A (ko) * | 2001-10-10 | 2005-04-15 | 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 | 가압 기체성 유체를 사용하는 분말 가공 |
US6890592B2 (en) * | 2002-03-13 | 2005-05-10 | Appleton Papers Inc. | Uniform microcapsules |
US6966990B2 (en) * | 2002-10-11 | 2005-11-22 | Ferro Corporation | Composite particles and method for preparing |
-
2004
- 2004-04-28 WO PCT/EP2004/004506 patent/WO2004096405A1/en active IP Right Grant
- 2004-04-28 KR KR1020057020462A patent/KR20060006949A/ko not_active Application Discontinuation
- 2004-04-28 DE DE602004016311T patent/DE602004016311D1/de not_active Expired - Lifetime
- 2004-04-28 NZ NZ543772A patent/NZ543772A/en unknown
- 2004-04-28 EP EP04729890A patent/EP1620193B1/en not_active Expired - Lifetime
- 2004-04-28 BR BRPI0409860-9A patent/BRPI0409860A/pt not_active IP Right Cessation
- 2004-04-28 MX MXPA05011626A patent/MXPA05011626A/es active IP Right Grant
- 2004-04-28 US US10/553,211 patent/US20060182808A1/en not_active Abandoned
- 2004-04-28 CA CA2523883A patent/CA2523883C/en not_active Expired - Fee Related
- 2004-04-28 ES ES04729890T patent/ES2312996T3/es not_active Expired - Lifetime
- 2004-04-28 CN CNB2004800113339A patent/CN100434133C/zh not_active Expired - Fee Related
- 2004-04-28 JP JP2006505309A patent/JP5207432B2/ja not_active Expired - Fee Related
- 2004-04-28 AT AT04729890T patent/ATE406946T1/de not_active IP Right Cessation
- 2004-04-28 RU RU2005136983/15A patent/RU2339364C2/ru active
- 2004-04-28 AU AU2004234057A patent/AU2004234057A1/en not_active Abandoned
- 2004-04-29 CL CL200400912A patent/CL2004000912A1/es unknown
- 2004-04-29 MY MYPI20041619A patent/MY141189A/en unknown
- 2004-04-29 TW TW093112056A patent/TW200500095A/zh unknown
- 2004-04-29 AR ARP040101476A patent/AR044140A1/es active IP Right Grant
-
2005
- 2005-10-27 IL IL171613A patent/IL171613A/en not_active IP Right Cessation
- 2005-11-28 NO NO20055607A patent/NO20055607L/no not_active Application Discontinuation
- 2005-11-28 ZA ZA200509597A patent/ZA200509597B/en unknown
-
2006
- 2006-08-10 HK HK06108874.8A patent/HK1088268A1/xx not_active IP Right Cessation
-
2011
- 2011-05-03 US US13/099,926 patent/US20110268806A1/en not_active Abandoned
-
2012
- 2012-05-25 US US13/481,088 patent/US20120232296A1/en not_active Abandoned
-
2013
- 2013-01-09 US US13/737,061 patent/US20130131029A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04154605A (ja) * | 1990-10-16 | 1992-05-27 | Agency Of Ind Science & Technol | 無機質微小球体の製造方法 |
JPH04193336A (ja) * | 1990-11-28 | 1992-07-13 | Fuji Photo Film Co Ltd | 溶液の均一混合装置および弾性体多孔膜 |
JPH07504162A (ja) * | 1991-12-18 | 1995-05-11 | ワーナー―ランバート・コンパニー | 新規な薬学的固体分散物 |
JPH11503448A (ja) * | 1995-04-13 | 1999-03-26 | アストラ・アクチエボラーグ | 吸引可能粒子の製造法 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7942990B2 (en) | 2006-12-18 | 2011-05-17 | Daicel Chemical Industries, Ltd. | Hybrid inflator |
JP2021500924A (ja) * | 2017-10-27 | 2021-01-14 | フリト−レー・ノース・アメリカ・インコーポレイテッドFrito−Lay North America, Inc. | ナトリウム低減用の結晶形態 |
JP7321169B2 (ja) | 2017-10-27 | 2023-08-04 | フリト-レー・ノース・アメリカ・インコーポレイテッド | ナトリウム低減用の結晶形態 |
WO2019239550A1 (ja) * | 2018-06-14 | 2019-12-19 | 日揮株式会社 | 晶析装置及び晶析方法 |
JPWO2019239550A1 (ja) * | 2018-06-14 | 2020-06-25 | 日揮株式会社 | 晶析装置及び晶析方法 |
US11857930B2 (en) | 2018-06-14 | 2024-01-02 | Jgc Corporation | Crystallization apparatus and crystallization method |
Also Published As
Publication number | Publication date |
---|---|
CA2523883C (en) | 2012-01-03 |
EP1620193A1 (en) | 2006-02-01 |
ZA200509597B (en) | 2006-12-27 |
BRPI0409860A (pt) | 2006-05-16 |
WO2004096405A1 (en) | 2004-11-11 |
MY141189A (en) | 2010-03-31 |
CL2004000912A1 (es) | 2005-02-04 |
AR044140A1 (es) | 2005-08-24 |
US20110268806A1 (en) | 2011-11-03 |
MXPA05011626A (es) | 2006-01-23 |
US20120232296A1 (en) | 2012-09-13 |
CN100434133C (zh) | 2008-11-19 |
AU2004234057A1 (en) | 2004-11-11 |
RU2339364C2 (ru) | 2008-11-27 |
HK1088268A1 (en) | 2006-11-03 |
DE602004016311D1 (de) | 2008-10-16 |
EP1620193B1 (en) | 2008-09-03 |
ATE406946T1 (de) | 2008-09-15 |
CA2523883A1 (en) | 2004-11-11 |
IL171613A (en) | 2010-02-17 |
TW200500095A (en) | 2005-01-01 |
ES2312996T3 (es) | 2009-03-01 |
NZ543772A (en) | 2009-05-31 |
JP5207432B2 (ja) | 2013-06-12 |
US20130131029A1 (en) | 2013-05-23 |
NO20055607D0 (no) | 2005-11-28 |
RU2005136983A (ru) | 2006-03-20 |
KR20060006949A (ko) | 2006-01-20 |
NO20055607L (no) | 2005-11-28 |
CN1780670A (zh) | 2006-05-31 |
US20060182808A1 (en) | 2006-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5207432B2 (ja) | アンチ溶媒凝固プロセス | |
HUT73733A (en) | Salmeterol xinafoate with controlled particle size | |
DK2326307T3 (en) | Process for the preparation of crystalline active substance microparticles | |
JP2006524565A5 (ja) | ||
US20070231398A1 (en) | Antisolvent Emulsion Solidification Process | |
Wu et al. | Nanocrystals: The preparation, precise control and application toward the pharmaceutics and food industry | |
Kurup et al. | Antisolvent crystallization: A novel approach to bioavailability enhancement | |
CN106456548A (zh) | 包括含药物活性物质化合物的多孔材料 | |
JP2009524654A (ja) | 有機化合物の沈殿方法 | |
JP4731980B2 (ja) | ステロール類の晶析方法およびそのシステム | |
US20170304207A1 (en) | Manufacture of a pharmaceutical product | |
JP2008507510A (ja) | 析出物の調製方法 | |
ES2523725T3 (es) | Procedimiento para la obtención de micro- o nanopartículas sólidas | |
Igarashi et al. | Control of Crystal Size Distribution and Polymorphs in the Crystallization of Organic Compounds | |
Dwyer | Nanocrystallization confined to porous matrices with and without surface functionalization effects | |
JP5594670B2 (ja) | 液−液界面を利用する被覆型複合物質の製造方法 | |
AU2005260816A2 (en) | Method of crystallizing bicalutamide | |
Ooshima et al. | DEVELOPMENT OF A NOVEL WWDJ-BATCH CRYSTALLIZER SUITABLE FOR PRODUCTION OF LARGE CRYSTALS WITH A NARROW CRYSTAL SIZE DISTRIBUTION AND CONTROL OF CRYSTAL POLYMORPHS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070427 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070427 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20071228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20071228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100517 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100817 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110224 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110509 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110516 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110623 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110722 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20120308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120403 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130122 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130215 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160301 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
LAPS | Cancellation because of no payment of annual fees |